Skip to main content
Evidence-led patent and technology research

Optimus Drugs P Ltd Received A Patent For 5 Piperazin L Yl Benzofuran 2 Carboxylic Acid Ethyl Ester

The archived GIPResearch article describes an Optimus Drugs process for preparing a benzofuran intermediate, giving application 2583/CHE/2014 and patent IN 316824. This identification is **disputed by another published source**: a Government of India DSIR patent compendium lists that exact application and patent number under 'Solid State Forms of Vilazodone Intermediates'. Until the official patent file resolves the discrepancy, the benzofuran story must be treated as an archival claim, not as verified patent scope or current status.

Save or follow this source
These actions open third-party AI services. Saving, citation, and future recall are not guaranteed.
GIPResearch illustration supporting Optimus Drugs P Ltd Received A Patent For 5 Piperazin L Yl Benzofuran 2 Carboxylic Acid Ethyl Ester
Research focusEvidence before conclusions

Identify source documents and material limitations relevant to the subject.

Decision contextClarify the technical question

Compare the available information with the specific invention or platform facts.

Research outputTraceable next steps

Document what is supported, uncertain or requires specialist analysis.

Substantive research and evidence

Optimus Drugs P Ltd Received A Patent For 5 Piperazin L Yl Benzofuran 2 Carboxylic Acid Ethyl Ester — research analysis

Verification alert: P0 CONFLICT: DSIR government compendium lists IN 316824 / 2583/CHE/2014 as SOLID STATE FORMS OF VILAZODONE INTERMEDIATES, inconsistent with old GIPResearch description.

Exact patent-family identification

The first task is identity reconciliation. Search the Indian register by both application and patent number, then compare title, applicant, priority, publication, specification and grant record. Names such as 'Optimus Drugs' and chemical intermediate titles can recur across unrelated patents. A shared applicant does not prove that two chemical technologies belong to one family. Obtain the authenticated grant and prosecution documents before labeling the benzofuran route patented. This step has higher priority than drafting a technical comparison from the disputed record. Evidence checkpoint: Compare the 2583/CHE/2014 register record with the DSIR publication naming vilazodone intermediates and the contradictory benzofuran title on WordPress. The record should include its issuing body, date, context and exact language. Where sources diverge, identify the conflict before converting this observation into a technical or legal conclusion.

Chemical structure and claim form

The article's chemical description refers to 5-piperazinyl-benzofuran-2-carboxylic acid ethyl ester, while the conflicting DSIR listing concerns solid-state forms of vilazodone intermediates. These subjects require different analysis. A process claim may be limited by reagent choice, step order or purification conditions; a solid-state form claim may require diffraction or other structural characterization. The named product in a patent title is not enough to select the correct claim category. Verify the actual chemical structures and examples before constructing any reaction-scheme illustration. Evidence checkpoint: Inspect the issued claim type before deciding whether the case concerns a synthetic process or solid-state-form characterization. Compare the result with a plausible alternative explanation, since similarity of terms is not proof of equivalence. A reviewer should be able to repeat the comparison using the same underlying material.

Preparation-route disclosure

Preparation-route analysis should compare starting materials, stoichiometry, intermediates, catalysts, reaction conditions, yield, impurity handling and safety controls—only to the extent the verified patent actually discloses them. Do not infer an 'industrial advantage' from the original article's marketing language. A chemical process can be more efficient under one condition and less suitable at production scale due to solvent recovery or hazard management. A defensible technical note needs the claim limitations and supporting examples, ideally compared with cited earlier process patents. Evidence checkpoint: Do not draft a reaction scheme until reagents, intermediates and experimental conditions are located in the matched specification. Retain the actual technical document or contractual clause supporting the finding. The decision-maker needs to know whether this is a binding limitation, a design option, or an unsupported assertion.

Visual framework for Optimus Drugs P Ltd Received A Patent For 5 Piperazin L Yl Benzofuran 2 Carboxylic Acid Ethyl Ester
Analytical illustration — use source documents for the underlying facts.

Novelty and inventive-step evidence

Patentability should be evaluated separately under novelty, inventive step and any applicable subject-matter exclusions. The original article summarizes an objection under section 3(d) of the Indian Patents Act, but the precise office action and applicant reply must be retrieved before repeating that procedural claim. A response claiming the invention is 'a process rather than a composition' is not itself proof of patentability. Identify which earlier disclosure the examiner relied on and which actual limitation the applicant asserted as novel. Evidence checkpoint: Seek the specific section 3(d) office action and response and distinguish the applicant's argument from a final Controller finding. Record both supporting and adverse materials. An unexplained gap or contradiction is a reason to narrow the claim, not to add confident wording to an informational webpage.

Status, ownership and expiry checks

Current rights analysis requires the most recent register record, not merely historical mention of a grant number. Verify renewal payments, expiry, restoration, recorded assignments and any litigation or opposition affecting the claim set. A granted patent may have narrower claims than its initial application, and ownership may change. A reader evaluating a synthetic route must also assess third-party patents and regulatory constraints independently. The present source set cannot establish that using a benzofuran process is free to operate or that it is currently restricted. Evidence checkpoint: Confirm expiry, renewal and owner only from a dated Indian register extract after the bibliographic contradiction is resolved. Use a source date and relevant geography when the legal or operational position can change. An old document may be valuable history but should not be presented as a current certification.

Technical comparison limits

Once identity is resolved, compare the actual claimed route or solid-state characterization against prior scientific and patent literature from before the correct priority date. A benzofuran synthesis review should look at reagent substitutions and process intermediates; a polymorph review should compare analytical signatures and preparation conditions. Mixing the two will produce false 'closest art' results. A negative patent search is meaningful only if the corpus, date, jurisdictions and structure-search methodology have been recorded. Evidence checkpoint: Use different prior-art corpora for a benzofuran route and vilazodone solid-state forms; combining them would produce misleading patent comparisons. Connect the outcome to a concrete next action: search a claim, change a document, test a control or ask for specialist review. A general statement of importance is not enough.

Original analytical framework and decision implications

The proposed original evidence artifact is a conflict-resolution ledger: WordPress statement, DSIR table entry, official registry title, exact application number, granted claim 1, owner and dated status. A second output is a chemistry claim-type comparison showing how process limitations differ from solid-state-form limitations, without treating either as the verified content of IN 316824 until the conflict is resolved. This is a P0 publication blocker for any present-tense benzofuran patent claim.

How to commission a reproducible evidence review

A useful research commission on chemical-process title conflict has a narrow scope: What is actually claimed in the reported Optimus Drugs benzofuran compound patent, and how should technical scope be verified?. The analyst should first establish the evidence relevant to exact patent-family identification and chemical structure and claim form, then test preparation-route disclosure and novelty and inventive-step evidence against competing evidence. Only after those records are compared should the report address status, ownership and expiry checks and technical comparison limits. The inquiry should record source identities, dates, assumptions, and contradictory documents. This order matters: a positive finding from one database, a promotional description, or an attractive technical diagram cannot resolve an unknown legal condition. Where the evidence is incomplete, the proper output is an explicit next search or test rather than a confident result.

Evidence register and research deliverables

A practical deliverable for chemical-process title conflict is a dated source-to-claim or source-to-control register, with one row for each of the six questions above. The first field records the proposition being tested; the second links to the primary evidence, and the third states what alternative explanation has been considered. For this page, the proposed distinctive output is: Claim-to-compound structure and route table only after identifying exact record. A research packet should also record which evidence is missing and who is authorized to make the consequential decision. The source hierarchy should start with DSIR versus official IP India record, then use technical publications and comparable records to interpret—not replace—the primary evidence. The resulting report should make the boundary between historical narrative, observed technical facts, legal interpretation and untested commercial hypotheses plain to readers.

Sources and verification boundaries

The following are authoritative sources or official discovery portals for the relevant methodology. A patent-office search portal is not itself evidence that any named patent currently remains in force. Claims about an individual case require its underlying file.

  • https://www.dsir.gov.in/sites/default/files/2023-09/Compendium_IPR_FI_2023.pdf
  • https://ipindia.gov.in/pages/e-services
  • https://patentscope.wipo.int/

Related research

Author and disclaimer

Research editorial draft for GIPResearch.com. The site is an information and research platform. This article is not personalized legal advice, a current patent-register certificate, a freedom-to-operate opinion, or a guarantee of any regulatory or commercial result. Verify material claims with current primary records. Full disclaimer.

Research checklist: what to verify before you decide

Use this checklist to assess the evidence behind optimus drugs p ltd received a patent for 5 piperazin l yl benzofuran 2 carboxylic acid ethyl ester rather than relying on a single summary or marketing claim.

  1. Exact patent-family identification
  2. Chemical structure and claim form
  3. Preparation-route disclosure
  4. Novelty and inventive-step evidence
  5. Status, ownership and expiry checks
  6. Technical comparison limits
  7. Original analytical framework and decision implications
  8. How to commission a reproducible evidence review

Official sources and research starting points

These are research starting points. Specific factual and legal conclusions require checking the underlying documents and dates.

  1. https://www.dsir.gov.in/sites/default/files/2023-09/Compendium_IPR_FI_2023.pdf
  2. https://ipindia.gov.in/pages/e-services
  3. https://patentscope.wipo.int/

Featured Work & Insights